Last reviewed · How we verify
PD-1 antibody
A PD-1 antibody blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, releasing immune checkpoint inhibition and allowing T cells to recognize and attack cancer.
A PD-1 antibody blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, releasing immune checkpoint inhibition and allowing T cells to recognize and attack cancer. Used for Advanced or metastatic solid tumors (specific indications under investigation in phase 3).
At a glance
| Generic name | PD-1 antibody |
|---|---|
| Also known as | Sintilimab, Camrelizumab, Toripalimab, PD-1 Inhibitors, SHR-1210 |
| Sponsor | Sun Yat-sen University |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
PD-1 (programmed death receptor 1) is an immune checkpoint that normally suppresses T cell activity. Tumors exploit this by expressing PD-L1 and PD-L2 ligands. By binding to PD-1, this monoclonal antibody prevents ligand engagement, restoring T cell proliferation, activation, and cytotoxic function against malignant cells. This mechanism has proven effective across multiple cancer types.
Approved indications
- Advanced or metastatic solid tumors (specific indications under investigation in phase 3)
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
- Rash
Key clinical trials
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) (PHASE1)
- Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma (PHASE2)
- Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (PHASE2)
- Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors (PHASE1)
- A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma (PHASE2)
- Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |